Search

Your search keyword '"Freeman, Gordon J."' showing total 1,869 results

Search Constraints

Start Over You searched for: Author "Freeman, Gordon J." Remove constraint Author: "Freeman, Gordon J."
1,869 results on '"Freeman, Gordon J."'

Search Results

101. Data from Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

102. Supp. Movie 1 from Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

103. Table S3 from Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

104. Supplementary Table 2 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade

105. Supplementay Figures S1-3 from Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer

106. Data from Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL

107. Data from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

108. Supplementary Figure Legends from BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non–Small Cell Lung Cancer

109. Table S1-S3; Figure S1-S13 from BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in Kras-Mutant Non–Small Cell Lung Cancer

110. Supplementary Data from Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

111. Supplementary Table 7 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade

112. Supplementary Table 1 from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

114. Data from Tumor PDCD1LG2 (PD-L2) Expression and the Lymphocytic Reaction to Colorectal Cancer

115. Data from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade

116. Table S1 from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

118. Supplementary Table 1 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade

119. Supplementary Figures from Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade

120. Supplemental Table I from PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells

121. Supplemental Table 1 from Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

122. Supplementary Figures 1 through 7 and Supplementary Table 1 from Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

124. Data from Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes

125. Supplemental Figure and Table Legends from PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells

126. Supplementary Table 3 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade

127. Supplementary Table 4 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade

128. Supplementary Table 6 from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade

129. Supplementary Figures from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

130. Supplementary Figures 1-3 from Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL

131. Supplementary Methods from MicroRNA MIR21 and T Cells in Colorectal Cancer

132. Supplementary Methods from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

133. Supplementary Methods from Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

136. Supplementary Figure Legends from Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

138. Supplementary Figures and Legends from Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade

139. Supplemental Table 2 from Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma

140. Supplementary Figure Legends from Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

141. Data from Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

142. Supplemental Figures and Tables from Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade

143. Supplementary Figure Legend from Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

144. Supplementary Tables 1 through 8 from Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition

145. Supplementary Figures from Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade

146. Supp. Movie 2 from Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

147. Supplementary Figure from Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma

148. Data from PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer

150. Table S1 from Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer

Catalog

Books, media, physical & digital resources